Akero Therapeutics, Inc. Interest Expense
Akero Therapeutics, Inc. reported Interest Expense of $1.09 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Expense Statement
us-gaap:InterestExpense · last filed 2025-11-07
- Akero Therapeutics, Inc. interest expense for the quarter ending 2025-09-30 was $1.09M, a 12.36% decline year-over-year.
- Akero Therapeutics, Inc. interest expense for the quarter ending 2025-06-30 was $1.17M, a 4.79% decline year-over-year.
- Akero Therapeutics, Inc. interest expense for the quarter ending 2025-03-31 was $1.15M, a 16.45% increase year-over-year.
- Akero Therapeutics, Inc. interest expense for the quarter ending 2024-12-31 was $1.20M, a 33.78% increase year-over-year.
- Akero Therapeutics, Inc. interest expense for fiscal 2024 was $4.67M, a 50.63% increase from fiscal 2023.
- Akero Therapeutics, Inc. interest expense for fiscal 2023 was $3.10M, a 319.35% increase from fiscal 2022.
- Akero Therapeutics, Inc. interest expense for fiscal 2022 was $739.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.09M 10-Q · filed 2025-11-07 | $2.26M derived: sum of 2 quarters · filed 2025-11-07 | $3.42M 10-Q · filed 2025-11-07 | $4.62M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | $1.17M 10-Q · filed 2025-08-08 | $2.33M 10-Q · filed 2025-08-08 | $3.53M derived: sum of 3 quarters · filed 2025-08-08 | $4.77M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-03-31 | $1.15M 10-Q · filed 2025-05-12 | $2.35M derived: sum of 2 quarters · filed 2025-05-12 | $3.60M derived: sum of 3 quarters · filed 2025-11-07 | $4.83M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.45M derived: sum of 2 quarters · filed 2025-11-07 | $3.68M derived: sum of 3 quarters · filed 2025-11-07 | $4.67M 10-K · filed 2025-02-28 |
| 2024-09-30 | $1.25M 10-Q · filed 2025-11-07 | $2.48M derived: sum of 2 quarters · filed 2025-11-07 | $3.47M 10-Q · filed 2025-11-07 | $4.37M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $1.23M 10-Q · filed 2025-08-08 | $2.22M 10-Q · filed 2025-08-08 | $3.12M derived: sum of 3 quarters · filed 2025-08-08 | $4.01M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $991.00K 10-Q · filed 2025-05-12 | $1.89M derived: sum of 2 quarters · filed 2025-05-12 | $2.78M derived: sum of 3 quarters · filed 2025-05-12 | $3.63M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $897.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.78M derived: sum of 2 quarters · filed 2025-02-28 | $2.64M derived: sum of 3 quarters · filed 2025-02-28 | $3.10M 10-K · filed 2025-02-28 |
| 2023-09-30 | $888.00K 10-Q · filed 2024-11-08 | $1.75M derived: sum of 2 quarters · filed 2024-11-08 | $2.20M 10-Q · filed 2024-11-08 | $2.56M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $857.00K 10-Q · filed 2024-08-09 | $1.31M 10-Q · filed 2024-08-09 | $1.68M derived: sum of 3 quarters · filed 2025-02-28 | $2.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $457.00K 10-Q · filed 2024-05-10 | $819.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.14M derived: sum of 3 quarters · filed 2025-02-28 | $1.20M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $362.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $686.00K derived: sum of 2 quarters · filed 2025-02-28 | $739.00K derived: sum of 3 quarters · filed 2025-02-28 | $739.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | $324.00K 10-Q · filed 2023-11-13 | $377.00K derived: sum of 2 quarters · filed 2023-11-13 | $377.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $53.00K 10-Q · filed 2023-08-11 | $53.00K 10-Q · filed 2023-08-11 |